ClinicalTrials.Veeva

Menu

Patient's Anastrozole Compliance to Therapy Programme (PACT)

AstraZeneca logo

AstraZeneca

Status

Terminated

Conditions

Breast Cancer

Treatments

Drug: Anastrozole

Study type

Observational

Funder types

Industry

Identifiers

NCT00555867
1033GR/0002

Details and patient eligibility

About

Approximately 60 specialised clinics and 420 office based gynaecologists or oncologists will participate in this in practice evaluation program (NIS). The clinic and approximately 7 office based physicians will collaborate within their breast centre networks to conduct this program. A breast centre network should be able to recruit in this program approximately 80 patients (approximately 40 patients per year). It is planned to enroll approximately 4674 patients in this NIS (2337 patients per arm). The patient population will include postmenopausal women with hormone-receptor positive primary breast cancer scheduled for upfront adjuvant endocrine treatment with anastrozole according to the current standard medical procedures.

Enrollment

4,923 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histological/cytological confirmed primary diagnosis of early breast cancer
  • Postmenopausal
  • Hormone receptor positive

Exclusion criteria

  • Patients with severe renal function disorders
  • Patients with moderate or severe disorders of hepatic function
  • Concomitant treatment with drugs known to affect sex hormonal status and tamoxifen

Trial design

4,923 participants in 2 patient groups

1
Description:
Standard routine care for breast cancer
Treatment:
Drug: Anastrozole
2
Description:
Standard + Intervention arm: standard routine care for breast cancer and additional information material via post
Treatment:
Drug: Anastrozole

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems